Parkinson’s disease is often described as a disorder of movement, but a new study highlights a biological difference that may be impossible to ignore: the sex of a patient can influence the molecular signature of familial Parkinson’s disease in the bloodstream. Published in npj Parkinson’s Disease, the research by C. Marino, F. Carrillo, M. Serra and colleagues examines how sex differences shape serum metabolome profiles in people with inherited forms of the condition.

The finding brings attention to a rapidly expanding area of Parkinson’s research. Rather than focusing on a single protein, gene or symptom, metabolomics examines thousands of small molecules circulating in a biological sample. These molecules include products of energy production, lipid processing, amino-acid metabolism and cellular signaling. Together, they form a biochemical snapshot of the body’s current physiological state, offering researchers a way to detect patterns that may be invisible through conventional clinical measurements.

In this study, the key biological material is serum, the clear fluid remaining after blood cells and clotting components are removed. Serum contains a constantly changing mixture of metabolites released by organs, muscles, immune cells and the nervous system. Because these compounds can respond to disease, medication, diet and systemic stress, serum metabolomics is increasingly being investigated as a source of biomarkers—measurable biological signals that could help characterize disease or predict how it develops.

The paper’s central message is that sex differences affect serum metabolome profiles among patients with familial Parkinson’s disease. Familial Parkinson’s disease refers to cases in which inherited genetic factors contribute substantially to disease risk. Although these forms represent only a portion of all Parkinson’s cases, they provide an important opportunity to investigate how genetic vulnerability interacts with biological characteristics, including sex-related physiology.

The researchers’ focus is significant because men and women can differ in hormone levels, immune activity, body composition, medication responses and energy metabolism. These differences may influence the concentrations of circulating metabolites, even when patients share the same broad neurological diagnosis. If sex-specific metabolic patterns are overlooked, researchers could mistakenly treat biologically distinct patient groups as though they were molecularly identical.

Metabolomic research is technically demanding. A typical analysis may use high-resolution analytical platforms capable of separating and identifying numerous compounds from a small volume of serum. Computational methods are then used to compare metabolic profiles between groups and to determine which molecular patterns are associated with clinical or biological variables. The resulting data can reveal coordinated changes in biochemical pathways rather than isolated shifts in individual molecules.

That distinction matters for Parkinson’s disease, a neurodegenerative disorder associated with the progressive loss of dopamine-producing neurons in a region of the brain involved in movement control. The disease also affects mitochondrial function, oxidative stress, inflammation and lipid biology—processes that leave chemical traces beyond the brain. Serum metabolomics cannot directly reproduce what is happening inside vulnerable neurons, but it may provide an accessible window into systemic changes linked to disease.

The study’s emphasis on familial disease may also help refine the search for precision medicine. A metabolic signature associated with one sex, or with a particular genetic background, might eventually support more tailored approaches to diagnosis, monitoring or treatment. However, a metabolic profile is not automatically a clinical biomarker. Researchers must determine whether the pattern can be reproduced in independent patient groups, whether it changes over time and whether it reflects Parkinson’s disease itself rather than age, diet, medication, lifestyle or another medical condition.

The findings also underscore why future Parkinson’s studies may need to treat sex as a central biological variable rather than a demographic detail. Understanding how inherited risk and sex-related biology combine could help explain why symptoms, disease progression and treatment responses vary from person to person. Marino, Carrillo, Serra and colleagues’ work adds to the growing evidence that the molecular story of Parkinson’s disease is more complex than a single universal disease pathway. By showing that serum metabolome profiles differ according to sex in familial Parkinson’s disease, the study points toward a more precise and biologically informed era of neurological research.

Subject of Research: Sex differences in serum metabolome profiles among patients with familial Parkinson’s disease.

Article Title: Sex differences impact serum metabolome profiles in patients with familial Parkinson’s disease.

Article References: Marino, C., Carrillo, F., Serra, M. et al. “Sex differences impact serum metabolome profiles in patients with familial Parkinson’s disease.” npj Parkinson’s Disease (2026). https://doi.org/10.1038/s41531-026-01511-8

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01511-8

Keywords: Parkinson’s disease, familial Parkinson’s disease, sex differences, serum metabolomics, metabolome profiles, biomarkers, precision medicine, neurodegeneration

Tags: biochemical signatures of Parkinson’s disease in blood serumblood metabolite profiles in familial Parkinson’s diseasegender-specific molecular signatures in neurodegenerative disordersinfluence of sex on blood-based Parkinson’s disease diagnosticslipid processing and amino acid metabolism in Parkinson’s diseasemetabolomics biomarkers for familial Parkinson’s diseaserole of serum metabolites in understanding Parkinson’s disease pathologyserum metabolome analysis in Parkinson’s diseasesex differences in Parkinson’s disease metabolomicssystemic stress and metabolic changes in Parkinson’s disease